Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit

BACKGROUND: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifi, Sharareh, Salimi, Babak, Esfahani-Monfared, Zahra, Radmanesh, Ramin, Yaghoubifard, Saeed, Talebianpour, Sara, Khosravi, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375593/
https://www.ncbi.nlm.nih.gov/pubmed/35485670
http://dx.doi.org/10.31557/APJCP.2022.23.4.1155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375593/
https://www.ncbi.nlm.nih.gov/pubmed/35485670
http://dx.doi.org/10.31557/APJCP.2022.23.4.1155

Ejemplares similares